PatientsVille.com LogoPatientsVille.com

Liver Cirrhosis | Multiparametric MR for Rapid Imaging Assessment of the Liver

Liver Cirrhosis research study

What is the primary objective of this study?

The RIAL study aims to investigate whether non-invasive measurement of liver fat, iron content and fibrosis are as accurate as liver biopsy specimens in determining if patients have non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), or other suspected liver disease. Currently, the gold-standard for the diagnosis and staging of liver disease is a liver biopsy. In this study, consecutive patients will be offered a multiparametric MR scan to assess their liver while they await a liver biopsy. Study time-frame: The scan will be performed in the 6-week period before their biopsy, and results will be compared to biopsy findings. results will be presented at the end of the study when MR data outcomes are compared to gold-standard biopsy dat. Participants will only have to attend one study visit to participate - there will be no patient follow-up.

Who is eligible to participate?

Inclusion Criteria: - Male or Female over 18 years of age due for diagnostic liver biopsy - Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: - Any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Liver Cirrhosis

Fatty Liver

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Liver Biopsy patientsAll patients due to have a liver biopsy for the assessment of parenchymal liver disease.

Study Status

Unknown status

Start Date: March 2011

Completed Date: September 2012

Phase:

Type: Observational

Design:

Primary Outcome: Liver fat content

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Eleanor Barnes, BSc MBBS PhD

Lead Sponsor: University of Oxford

Collaborator: British Heart Foundation

More information:https://clinicaltrials.gov/show/NCT01543646

Discuss Liver